Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2019 Earnings Conference Call - Final Transcript
Nov 05, 2019 • 04:30 pm ET
have described on previous calls to occur during the first quarter of 2020.
With that I'd like to turn the call back over to Raul.
Raul R. Rodriguez
Thank you Dean. Before we turn the call over to your questions I'd like to reiterate the 4 key areas that continue to drive value for Rigel. The first is our current commercial business in the U.S. which we continue to grow and we will support further with post-hoc data analysis providing insight on earlier use of our product. This data will be expected -- is expected to be presented at the upcoming ASH conference which takes place in early December. Second outside of the U.S. there is a substantial market opportunity and we are making fostamatinib available to patients worldwide beginning in Europe next year. Third we are capitalizing on the potential of TAVALISSE to treat warm autoimmune hemolytic anemia. Not only is this a dynamic opportunity for Rigel because of a lack of FDA-approved therapies but there are tremendous synergies with our current ITP business. And then fourth the cornerstone of our company is the productivity of our R&D team and our pipeline of attractive opportunities that they have produced. Our SYK RIP1 and IRAK1/4 programs are attractive value drivers for Rigel in the long term and in the short term via our own commercialization and via partnerships.
With that let me turn the call over to your questions. Operator?